Aprepitant/Palonosetron Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Aprepitant/Palonosetron Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 23 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Aprepitant/Palonosetron can convert its Small molecule drug profile and HTR3 x NK1R biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Aprepitant/Palonosetron (query alias: Aprepitant/Palonosetron) |
|---|---|
| Modality / target | Small molecule drug; HTR3 x NK1R; 5-HT3 receptor antagonists, NK1R antagonists |
| Highest global status | NDA/BLA |
| Originator | Qilu Pharmaceutica Hainanco Ltd. |
| Active developers | Qilu Pharmaceutica Hainanco Ltd. |
The MCP disease footprint includes Chemotherapy-induced nausea and vomiting. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07639723 | Phase 4 | Not yet recruiting | 350 | difference in the incidence of same-day discharges between two randomized groups of anti-emetic regimens for anesthesia care |
| ChiCTR2600119505 | Phase 4 | Pending | 162 | Postoperative nausea and vomiting 30-minute complete remission rate |
| NCT07371728 | Phase 4 | Not yet recruiting | 100 | Incidence of clinically important postoperative nausea and vomiting |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Extended aprepitant in control of delayed emesis during induction chemotherapy for acute myeloid leukaemia – an multicentric, investigator-initiated, open label randomized controlled trial
Not Applicable; n=204; evaluation: Negative. Reported fields: AE = Adverse effect profile including febrile neutropenia or its complications, also did not differ between the two groups. ; AE = Adverse effect profile including febrile neutropenia or its complications, also did not differ between the two groups.
Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting
Not Applicable; n=1; evaluation: Positive. Reported fields: Efficacy = After just one week of applying HT-001 2% cream twice daily, the patient experienced full symptom and lesion resolution, with no recurrence of lesions in the following three weeks.
Hoth Therapeutics Achieves Breakthrough in Phase 2a Trial: HT-001 Delivers 100% Success in Combating Cancer Treatment Skin Toxicities
Phase 2; n=not disclosed; evaluation: Positive. Reported fields: ARIGA ≤1 = 100 % Met
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Aprepitant/Palonosetron addresses Chemotherapy-induced nausea and vomiting. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 6 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2024-04-09 | Nanoform and PlusVitech partner to repurpose aprepitant as a treatment for lung cancer | Preclinical | Financial terms not disclosed |
| 2023-03-08 | Washington University plans to conduct a phase IIa study on Hoth's HT-001 for the treatment of rash and skin disorders. | Phase 2 | Financial terms not disclosed |
| 2022-02-08 | Oxilio signes a contract with Quotient Sciences to support the formulation development of NXP-001 | Phase 1 | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 23 July 2026. Counts and status fields may change as source records update.
